Exelon vs. Placebo in Delaying Alzheimer's Disease Diagnosis in MCI Patients

This study is a phase IIIb trial looking into the delay of Alzheimer's disease diagnosis in individuals with mild cognitive impairment (MCI). The trial focuses on comparing the time it takes for MCI to progress to Alzheimer's disease in participants taking a drug called Exelon versus those taking a placebo. Exelon is currently under review by the U.S. Food and Drug Administration for Alzheimer's disease treatment and is already approved in over 40 countries, including the European Union and several countries in the Americas. The study aims to provide valuable insights into the potential benefits of Exelon in delaying Alzheimer's disease progression. Participants with MCI will be randomly assigned to receive either Exelon or a placebo. Those in the Exelon group will take 1.5 to 6.0 mg twice daily (3.0 to 12 mg/day) for most of the study duration. Every three months, patients will attend regular visits for basic safety and effectiveness assessments. These visits will include evaluations of any adverse events, vital signs, daily living activities, and clinical staging scales to determine if the participant's condition may have progressed to dementia.